GnRH antagonists and endometrial receptivity in oocyte recipients: a prospective randomized trial

Prapas, Nikos; Tavaniotou, Asimina; Panagiotidis, Yannis; Prapa, S.; Kasapi, Evangelia; Goudakou, Maria; Papatheodorou, Achilleas; Prapas, Yannis

doi:10.1016/s1472-6483(10)60266-0

Cited by 25 publications

(17 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The low implantation and pregnancy rate may be due to the effect of supraphysiological serum estradiol concentrations and GnRH antagonist administration on endometrial receptivity. 21 , 22 So that, when the peak E2 level per oocyte exceed 400 pg/mL, patients should avoid fresh embryo transfer and all embryos should be cryopreserved for frozen-thawed embryos transfer. The peak E2 level/oocyte less than 100 pg/mL indicates that the oocytes are immature.…”

Section: Discussionmentioning

confidence: 99%

New Perspectives on Criteria for the Determination of HCG Trigger Timing in GnRH Antagonist Cycles

Luo

Huang

et al. 2016

Medicine

View full text Add to dashboard Cite

The aim of this study was to investigate 2 quantification criteria to evaluate the developmental condition of follicles cohort and clarify their impacts upon the determining of human chorionic gonadotropin trigger timing and the reproductive outcome: the proportion of mature follicles in growing follicles cohort on the day of human chorionic gonadotropin trigger and the peak estradiol level per oocyte on the day of human chorionic gonadotropin administration.Of the patients who underwent in vitro fertilization/ intracytoplasmic sperm injection-embryo transfer from 2011 to 2013, 492 controlled ovarian hyperstimulation cycles using gonadotropin-releasing hormone antagonists reaching the ovum pick-up and fresh embryo-transfer stage were included. Patients were divided into 3 groups according to their ≥17 mm/≥10 mm follicles ratio on the day of human chorionic gonadotropin administration (Low proportion: ≤30%, Middle proportion: 30%–60%, High proportion: ≥60%). Patients were divided into 5 groups according to their peak estradiol level/oocyte (Group A: <100 pg/mL per oocyte, Group B: 100–199 pg/mL per oocyte, Group C: 200–299 pg/mL per oocyte, Group D: 300–399 pg/mL per oocyte, Group E ≥400 pg/mL per oocyte) as well. Comparison among groups was made regarding ovarian stimulation characteristics, fertilization rate, good quality embryo rate, implantation, pregnancy, and live birth rates.On the basis of ≥17 mm/≥10 mm follicles ratio, the number of oocyte retrieved in low proportion group is more than other 2 groups. Implantation rate, clinical pregnancy, and live birth rate in high proportion group were 25.8%, 42.7%, and 31.1%, respectively, which is highest in 3 groups, and statistical significance existed between high and middle proportion groups. When the division is based on peak estradiol level/oocyte, the number of oocyte retrieved of ≥400 pg/mL per oocyte Group was significantly lowest compared with the other 4 groups. Matured ovum rate, fertilization rate, and good quality embryos rate exhibited an increasing trend as the peak estradiol level/oocyte increased. While pregnancy rate, implantation rate, and live birth rate were found to be lower whenever estradiol/oocyte ratio exceeded 400 pg/mL per oocyte or less than 100 pg/mL per oocyte, and there is statistical difference.Patients with the proportion of mature follicle reaching 60% on the day of human chorionic gonadotropin trigger and peak estradiol/oocyte level within 100∼399 pg/mL range can get a better pregnancy and implantation rate.

show abstract

Section: Discussionmentioning

confidence: 99%

New Perspectives on Criteria for the Determination of HCG Trigger Timing in GnRH Antagonist Cycles

Luo

Huang

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

“…In the recent study, Prapas et al [20] studied the effects of GnRH antagonists on endometrial receptivity in oocyte donation cycles. Their study showed that use of antagonists in dose of 0.25 mg per day did not effect either the endometrial development or the pregnancy rate.…”

Section: Discussionmentioning

confidence: 99%

The relationship between endometrial thickness and pregnancy rates in GnRH antagonist down-regulated ICSI cycles

Kinay

Taşçı

Dilbaz

et al. 2010

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

“…Higher pregnancy rates were also shown in a gonadotropin intrauterine insemination cycle than in a cycle where no intervention took place [57]. In a prospective randomized trial, Prapas et al [58] reported that GnRH antagonist administration during the proliferative phase did not adversely affect endometrial receptivity in oocyte recipients.…”

Section: Introductionmentioning

confidence: 99%

Optimal usage of the GnRH antagonists: a review of the literature

Copperman

Benadiva

2013

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Gonadotropin-releasing hormone (GnRH) antagonists, which became commercially available from 1999, have been used for the prevention of premature luteinizing hormone (LH) surges in controlled ovarian stimulation for in vitro fertilization or intracytoplasmic sperm injection. This review focuses on the recent literature on the use of GnRH antagonists and provides guidelines for optimal use in light of increasing evidence showing that GnRH antagonists are safe and effective, allowing flexibility of treatment in a wide range of patient populations. This includes patients undergoing first-line controlled ovarian stimulation, poor responders, and women diagnosed with polycystic ovary syndrome. The GnRH antagonist offers a viable alternative to the long agonists, providing a shorter duration of treatment with fewer injections and with no adverse effects on assisted reproductive technology outcome. This results in a significantly lower amount of gonadotropins required, which is likely to lead to improved patient compliance.

show abstract

GnRH antagonists and endometrial receptivity in oocyte recipients: a prospective randomized trial

Cited by 25 publications

References 43 publications

New Perspectives on Criteria for the Determination of HCG Trigger Timing in GnRH Antagonist Cycles

New Perspectives on Criteria for the Determination of HCG Trigger Timing in GnRH Antagonist Cycles

The relationship between endometrial thickness and pregnancy rates in GnRH antagonist down-regulated ICSI cycles

Optimal usage of the GnRH antagonists: a review of the literature

Contact Info

Product

Resources

About